Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Mark W Kroll is Director at Haemonetics. OQRO lists 2 transactions filed with the SEC under this name, the latest on Jul 28, 2026, each linked to the official Form 4.
Director
Disclosures on record
2
Companies involved
1
Mark W Kroll bought shares on the open market in 2025 across 2 companies. Sales in 10 of the 15 years since 2012.
Mark W Kroll reported 1 open-market purchase and 39 sales since 2012; purchases in 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $99K1×1 trade | — |
| 2023 | — | $783K2×2 trades |
| 2022 | — | $916K2×2 trades |
| 2021 | — | $1.18M2×2 trades |
| 2020 | — | $1.47M3×3 trades |
| 2019 | — | $268K1×1 trade |
| 2018 | — | $2.13M3×3 trades |
| 2017 | — | $356K21×21 trades |
| 2015 | — | $507K1×1 trade |
| 2014 | — | $71K1×1 trade |
| 2012 | — | $2.27M3×3 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
1 buy, median −25.2 pts vs S&P 500, beat it 0 of 1 time.
Average −25.2 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Nov 12, 2025 to Nov 12, 2025, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 0% of the 1 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 83 ranked insiders is −6.0 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
HaemoneticsHAE
2 disclosures · Nov 2025 – Jul 2026 · 1 bought
Jul 24, 20262,538disclosed Jul 28
DetailsOfficial recordNov 10, 2025Bought~$99Kdisclosed Nov 12
DetailsOfficial recordAs of the latest filing on , Mark W Kroll reported holding 27,295 shares of Haemonetics (HAE), worth about $3.31M at the last close of $121 (Nov 16, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Haemonetics HAE | 27,295 | 27K direct | $121 | $3.31M | Jul 24, 2026 |
Is this Mark W Kroll’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Mark W Kroll reported 1 open-market purchase and 31 sales here, 2012 to 2025.
Mark W Kroll reported 0 open-market purchases and 8 sales here, 2014 to 2023.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
On the latest SEC Form 4, dated Jul 24, 2026, Mark W Kroll reported holding 27,295 shares of Haemonetics (HAE). At the last close of $121 on Nov 16, 2026, that is about $3.31M. This is the stake disclosed in filings, not a net worth.
Mark W Kroll bought shares on the open market in 2025 across 2 companies. Sales in 10 of the 15 years since 2012.
In SEC filings since 2012: the latest open-market purchase is from 2025; the latest open-market sale is from 2023.
2 companies: Haemonetics (HAE, 2012–2025), Axon Enterprise (AXON, 2014–2023).